DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme

Information source: M.D. Anderson Cancer Center
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Brain and Central Nervous System Tumors

Intervention: Celecoxib (Drug); Isotretinoin (Drug); Temozolomide (Drug); Thalidomide (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: M.D. Anderson Cancer Center

Official(s) and/or principal investigator(s):
Marta Penas-Prado, MD, Study Chair, Affiliation: M.D. Anderson Cancer Center


RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Thalidomide may stop the growth of glioblastoma multiforme by blocking blood flow to the tumor. Isotretinoin may help cells that are involved in the body's immune response to work better. Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known which temozolomide-containing regimen is more effective in treating glioblastoma multiforme. PURPOSE: This randomized phase II trial is studying eight different temozolomide-containing regimens to compare how well they work in treating patients who have undergone radiation therapy for glioblastoma multiforme.

Clinical Details

Official title: A Randomized, Factorial-Design, Phase II Trial of Temozolomide Alone and in Combination With Possible Permutations of Thalidomide, Isotretinoin and/or Celecoxib as Post-Radiation Adjuvant Therapy of Glioblastoma Multiforme

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Primary outcome: Progression-free survival at 6 months

Detailed description: OBJECTIVES:

- Compare the efficacy of adjuvant temozolomide (TMZ) alone or in combination with

thalidomide and/or isotretinoin and/or celecoxib, in terms of 6-month progression-free survival, in patients who have undergone radiotherapy for supratentorial glioblastoma multiforme.

- Compare the toxicity of these regimens in these patients.

OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 8 treatment arms.

- Arm I: Patients receive oral temozolomide once daily on days 1-7 and 15-21.

- Arm II: Patients receive temozolomide as in arm I and oral thalidomide once daily on

days 1-28.

- Arm III: Patients receive temozolomide as in arm I and oral isotretinoin twice daily on

days 1-21.

- Arm IV: Patients receive temozolomide as in arm I and oral celecoxib twice daily on

days 1-28.

- Arm V: Patients receive temozolomide as in arm I, thalidomide as in arm II, and

isotretinoin as in arm III.

- Arm VI: Patients receive temozolomide as in arm I, thalidomide as in arm II, and

celecoxib as in arm IV.

- Arm VII: Patients receive temozolomide as in arm I, isotretinoin as in arm III, and

celecoxib as in arm IV.

- Arm VIII: Patients receive temozolomide as in arm I, thalidomide as in arm II,

isotretinoin as in arm III, and celecoxib as in arm IV. In all arms, treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patient may receive additional courses of therapy at the discretion of the treating physician. After completion of study treatment, patients are followed for at least 30 days and then every 3 months thereafter. PROJECTED ACCRUAL: A total of 180 patients will be accrued for this study.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.



- Histologically confirmed supratentorial glioblastoma multiforme

- Must have undergone a biopsy OR subtotal or gross total resection of the tumor

- Must have completed post-operative (or post-biopsy) radiotherapy within the past 5


- No progressive disease after radiotherapy


- 18 and over

Performance status

- Karnofsky 60-100%

Life expectancy

- Not specified


- Absolute neutrophil count ≥ 1,500/mm^3

- Platelet count ≥ 100,000/mm^3


- Serum glutamate pyruvate transaminase (SGPT) < 2 times upper limit of normal (ULN)

- Alkaline phosphatase < 2 times ULN

- Bilirubin ≤ 1. 5 mg/dL


- blood urea nitrogen (BUN) ≤ 1. 5 times ULN

- Creatinine ≤ 1. 5 times ULN


- No history of allergic reactions attributed to compounds of similar chemical or

biological composition to celecoxib or to sulfonamides

- No asthma, urticaria, or allergic reactions to aspirin or other NSAIDs

- No active infection


- No inflammatory bowel disease

- No history of peptic ulcer disease

- No gastrointestinal bleeding within past 3 months


- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective double-method contraception during and for 2

months after study participation

- Fertile female patients randomized to receive thalidomide must use effective

double-method contraception for ≥ 4 weeks before, during, and ≥ 4 weeks after completion of study therapy

- Fertile male patients randomized to receive thalidomide must use effective

contraception during and for ≥ 4 weeks after completion of study therapy

- No blood donation (for patients randomized to receive thalidomide)

- No history of any other cancer except nonmelanoma skin cancer or carcinoma in situ of

the cervix or cancer that is in complete remission and patient completed all therapy for that disease ≥ 3 years ago

- No other disease that would obscure toxicity or dangerously alter drug metabolism

(e. g., severe connective tissue disease)

- No other serious medical illness


- Not specified


- Prior temozolomide in combination with radiotherapy allowed

- No other prior or concurrent chemotherapy

Endocrine therapy

- Not specified


- See Disease Characteristics

- See Chemotherapy


- See Disease Characteristics

- No concurrent surgery


- No other concurrent non-steroidal anti-inflammatory drugs (NSAIDs) (for patients

randomized to receive celecoxib)

- No other concurrent investigational drugs

- No other concurrent anticancer therapy

Locations and Contacts

Hembree Mercy Cancer Center at St. Edward Mercy Medical Center, Fort Smith, Arkansas 72913, United States

University of Texas MD Anderson Cancer Center at Orlando, Orlando, Florida 32806-2134, United States

CCOP - Atlanta Regional, Atlanta, Georgia 30342-1701, United States

CCOP - Central Illinois, Decatur, Illinois 62526, United States

CCOP - Wichita, Wichita, Kansas 67214-3882, United States

CCOP - Grand Rapids, Grand Rapids, Michigan 49503, United States

CCOP - Kalamazoo, Kalamazoo, Michigan 49007-3731, United States

CCOP - Kansas City, Kansas City, Missouri 64131, United States

Cancer Research for the Ozarks, Springfield, Missouri 65804, United States

Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210-1240, United States

CCOP - Upstate Carolina, Spartanburg, South Carolina 29303, United States

University of Texas MD Anderson Cancer Center, Houston, Texas 77030-4009, United States

Additional Information

Clinical trial summary from the National Cancer Institute's PDQ® database

University of Texas (UT) MD Anderson Cancer Center Official Website

Starting date: September 2005
Last updated: September 23, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017